MetaCap

Immunic Inc. (IMUX)

NASDAQ: IMUXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

6.99-0.40 (-5.41%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IMUX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$111.01M
EPS (TTM)
-$3.53
52-week range
5.06 – 17.43
Day range
6.97 – 7.56
Volume / Avg
295.91K / 343.44K
Beta
—

52-week range

$5.06$17.43

IMUX stock today

Immunic (IMUX) closed at $6.99 on Nov 20, down 5.41% (-$0.40), versus the S&P 500's 3.70% decline. Shares are 59.9% below their 52-week high of $17.43, set on Aug 19, 2026 and 38.1% above the 52-week low of $5.06, near the bottom of the past year's range. IMUX is up 30.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 1.9%.

Immunic has posted a net loss over the last twelve months (EPS of -$3.53), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Immunic

Company profile

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Erik Lundgren
Headquarters
New York, NY
Employees
100
IPO year
2014
Website
imux.com

Financial highlights

Full financials

Immunic reported a net loss of $97.2 million, compared with a loss of $100.5 million a year earlier. Diluted earnings per share came in at -$0.62.

Immunic annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-97.17M$-100.51M$-93.61M$-120.41M$-92.94M
EPS (diluted)$-0.62$-1.00$-2.11$-3.78$-3.93

Analyst forecast

Forecast

Consensus (13 analysts)

strong_buy

Avg. price target

$42.55+508.73%

  • Strong buy 0
  • Buy 13
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $20.00High $85.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-0.99 vs $-0.82
Surprise
-20.73%

IMUX news

All IMUX news

Immunic peers

Health Care sector
IMUX peer companies
CompanyPrice% ChgMarket capCompare
OKUROnKure Therapeutics Inc. Class A2.70-2.17%$111.21Mvs IMUX
MENSJyong Biotech Ltd.1.45-17.14%$110.24Mvs IMUX
SPRBSpruce Biosciences Inc.38.00-6.15%$109.21Mvs IMUX
BGMBGM Group Ltd. Class A8.130.00%$108.57Mvs IMUX
AKBAAkebia Therapeutics Inc.0.3855-8.71%$107.04Mvs IMUX
ADAGAdagene Inc. ADR1.76-12.44%$118.17Mvs IMUX
GNLXGenelux Corporation2.17-4.82%$103.36Mvs IMUX
FHTXFoghorn Therapeutics Inc.1.72-3.37%$103.14Mvs IMUX

Indexes, lists and sector

Immunic stock FAQ

What is Immunic's stock price today?

IMUX last traded at $6.99 as of Nov 20, 4:00 PM EST, down 5.41% on the day. Prices are delayed at least 15 minutes.

Does Immunic pay a dividend?

No. Immunic does not currently pay a regular cash dividend.

Who is Immunic's CEO?

Mr. Erik Lundgren is the chief executive officer of Immunic Inc., which has about 100 employees.

Has IMUX ever split its stock?

Yes. The most recent IMUX stock split was a 1-for-10 split on Apr 27, 2026, one of 2 splits on record.

What is the IMUX 52-week high?

The 52-week high for IMUX is $17.43 and the 52-week low is $5.06. The stock is currently 59.9% below its high.

Compare IMUX